Molineaux Christopher P. 4
4 · Aclaris Therapeutics, Inc. · Filed Jun 22, 2023
Insider Transaction Report
Form 4
Molineaux Christopher P.
Director
Transactions
- Exercise/Conversion
Common Stock
2023-06-20$1.41/sh+16,500$23,265→ 48,503 total - Exercise/Conversion
Stock Option (right to buy)
2023-06-20−16,500→ 0 totalExercise: $1.41Exp: 2030-06-03→ Common Stock (16,500 underlying)
Footnotes (1)
- [F1]The shares underlying this option vested in twelve equal monthly installments commencing July 4, 2020, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.